NewGenIvf Provides Update on Potential Reverse Merger with COVIRIX
BANGKOK, July 24, 2024 (GLOBE NEWSWIRE) — NewGenIvf Group (NASDAQ:NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced an update on its proposed reverse merger (the “Proposed Transaction”) with pharmaceutical company COVIRIX Medical Pty Ltd (“COVIRIX”). The Company reports steady progress in its due diligence efforts and, contingent upon meeting all regulatory requirements, anticipates completing the Proposed Transaction by the end of August 2024.